Sei Investments Co. Acquires 45,851 Shares of Protagonist Therapeutics, Inc. $PTGX

Sei Investments Co. lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 122.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 83,197 shares of the company’s stock after buying an additional 45,851 shares during the quarter. Sei Investments Co.’s holdings in Protagonist Therapeutics were worth $8,769,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in Protagonist Therapeutics by 27.2% during the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after acquiring an additional 1,156,461 shares during the period. State Street Corp boosted its stake in Protagonist Therapeutics by 18.5% during the second quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after acquiring an additional 500,924 shares in the last quarter. Wellington Management Group LLP grew its holdings in Protagonist Therapeutics by 66.2% in the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after purchasing an additional 1,262,977 shares during the period. UBS Group AG increased its stake in shares of Protagonist Therapeutics by 46.1% during the fourth quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock valued at $241,934,000 after purchasing an additional 874,013 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Protagonist Therapeutics by 140.7% during the fourth quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock valued at $231,355,000 after purchasing an additional 1,549,160 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Bryan Giraudo sold 6,000 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $100.00, for a total transaction of $600,000.00. Following the sale, the director directly owned 31,825 shares in the company, valued at approximately $3,182,500. This trade represents a 15.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the completion of the sale, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. The trade was a 12.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 161,130 shares of company stock worth $16,355,220. Insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Stock Down 1.4%

NASDAQ:PTGX opened at $136.64 on Friday. The company’s 50 day moving average price is $120.38 and its 200-day moving average price is $103.23. Protagonist Therapeutics, Inc. has a 52 week low of $50.49 and a 52 week high of $143.29. The stock has a market cap of $8.79 billion, a price-to-earnings ratio of -75.49 and a beta of 1.79.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The company had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. As a group, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 3.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Citizens Jmp boosted their price target on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Barclays raised their price objective on Protagonist Therapeutics from $119.00 to $151.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. Citigroup reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group reissued a “neutral” rating and issued a $110.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Finally, Truist Financial increased their target price on Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $123.00.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.